{"id":3281,"date":"2017-04-07T05:04:12","date_gmt":"2017-04-07T09:04:12","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=3281"},"modified":"2025-09-20T19:10:14","modified_gmt":"2025-09-21T01:10:14","slug":"letermovir-top-line-results-they","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2017\/04\/07\/3281\/letermovir-top-line-results-they\/","title":{"rendered":"The Letermovir Top-Line Results are Out \u2013 Or Are They?"},"content":{"rendered":"

\"\"<\/a><\/p>\n

Usually, as development progresses from preclinical to a more advanced clinical stage, reality begins to set in: problems become apparent that were not anticipated, efficacy may be less than expected or hoped for, and the safety margins may shrink to a single-digit factor. In other words, as more data accrue, irrational exuberance tends to fades away replaced by cold facts and a therefore more realistic assessment.<\/p>\n

Finally there is sometimes the recognition that the product never deserved all the hype and praise from the outset.<\/p>\n

Letermovir (AIC246, MK8228) followed a different trajectory: each new morsel of clinical data made it look better as development progresed.<\/p>\n

Here is a quick summary of letermovir\u2019s features: It is a new antiviral with a novel MoA, a terminase inhibitor specific for CMV. Letermovir can for added efficacy be combined with the older ganciclovir, a DNA polymerase inhibitor. Devoid of a mammalian target, it is highly selective for the viral enzyme that operates by cutting CMV DNA strands from the rolling circle for packaging into capsids. The drug is incredibly active, with an EC50<\/sub> against CMV in the low nano-molar range making it approx. 1000x more potent than ganciclovir. It is well absorbed, has a long half-live (10 h), and is excreted primarily via the biliary route.[1]<\/a><\/p>\n

Not all is golden, though. The drug does inhibit several cytP450 enzymes, most notably 3A4.\u00a0 Hence, we would expect a number of drug-drug interactions, esp. in concert with anti-rejection drugs.<\/p>\n

\"\"<\/a>
From: Chemaly, NEJM 2014;370:1781<\/figcaption><\/figure>\n

In a sizeable (N=131) double-blind Phase 2 study in HCT patients, increasing doses of letermovir were administered prophylactically for 12 weeks after engraftment. There was a statistically significant dose-dependent response compared to placebo; letermovir treatment reduced the incidence rate of significant CMV infections from 64% (placebo) to 29% (letermovir high dose). After excluding patients with documented viral replication at entry, there were no virologic failures in the high-dose 240 mg PO qd letermovir arm. Importantly, renal or bone marrow toxicity were not detected.\u00a0 Can it get better than that?<\/p>\n

In a smaller study in renal transplant patients, the drug was also well tolerated and showed efficacy.<\/p>\n

So, when Merck informed us on October 19, 2016 that the drug had \u201cmet its primary endpoint\u201d in a pivotal Phase 3 trial resulting in reduction of clinically significant CMV infection, we were truly excited. We had high hopes for letermovir and were keen to hear the full story, the rest of the story.\u00a0 But Merck was tight-lipped about efficacy details, there was not a word about safety \/ tolerability.\u00a0 Further information was promised at a \u2018future scientific meeting\u2019.<\/p>\n

The next news tidbits came to us from the BMT Tandem Meeting this February[2]<\/a>,[3]<\/a>. However, the information provided was very sparse. We refrain from repeating the few snippets of information made public in various press releases[4]<\/a>. The Oncology Nurse Advisor sums it up well enough: \u201cLetermovir reduces CMV infection, improves survival\u201d.[5]<\/a><\/p>\n

Clearly this cannot be not the full story. We know for a fact that the drug was unable to prevent CMV recurrence in almost 40% of patients, a very disappointing finding which raises all kinds of questions. Was the 480 mg qd dosing regimen adequate; was the dose-adjustment for cyclosporine-treated patients optimal?\u00a0 What were the PK profiles of patients for whom prophylaxis failed?\u00a0 Why, when and in which subpopulations of HSC patients did CMV recur?\u00a0 Was CMV suppression achieved at least until engraftment, ie., when ganciclovir could safely be administered? What is the genomic make-up or resistance profile of the break-through viruses?\u00a0 Also, why was the incidence of GvHD not reduced in the letermovir arm?<\/p>\n

What was taking Merck so long to present the letermovir data in a comprehensive fashion? Where was the detailed press release that we would expect from a company that had just hit the jackpot? Was Merck too busy with its Keytruda studies that everything else was taking a back seat? One of the last AiCuris publications was in the New England Journal of Medicine, but any peer-reviewed journal would have sufficed.<\/p>\n

If Merck\u2019s publication strategy sounds strange to you, you are not alone. It reminds us of a Conan Doyle story, the case in which the dog did not bark \u2013 and yes, this lack of publicity is a curious incident.\u00a0

Beware of the man that does not talk, and the dog that does not bark<\/span><\/strong><\/em><\/p>\n<\/div><\/p>\n

When Big Pharma takes over development from a small VC, development, medical affairs and marketing decision making switches hands. Letermovir was the one and only project at AiCuris for a long time, but now the original developers were just coming along for the ride. Most VCs have to relinquish control when they sell to a big name, deep pockets pharma company whose actions are driven by competing projects and interests and \u2013 borrowing from chaos theory – other \u2018strange attractors\u2019.<\/p>\n

Delayed publication has happened before but after the disappointment with maribavir (ViroPharma) and brincidofovir (Chimerix), we were looking forward to a break, and hopeful for letermovir. Hence, we were anxious to learn from this important trial.<\/p>\n

We have been waiting a long time for a ganciclovir replacement and can wait a bit longer for Merck to get its act together. But without full disclosure of the Phase 3 letermovir study data, we are not yet ready to join in the cheerleading.<\/p>\n

References:
\n<\/strong>[1]<\/a> L Bowman. Letermovir for the management of cytomegalovirus infection. Expert Opinion on\u00a0Investigational Drugs, DOI: 10.1080\/13543784.2017.1274733
\n[2]<\/a> http:\/\/www.healio.com\/infectious-disease\/nosocomial-infections\/news\/online\/%7B5272bcfb-ea53-465d-b3a6-209633c01805%7D\/letermovir-effective-as-prophylaxis-for-cmv-in-high-risk-hct-patients
\n[3]<\/a> 2017 Bone Marrow Transplant Tandem Meetings of the American Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) in Orlando, Florida, February 22, 2017
\n[4]<\/a> https:\/\/www.drugs.com\/clinical_trials\/merck-s-letermovir-investigational-antiviral-medicine-prevention-cytomegalovirus-cmv-infection-bone-17339.html
\n[5]<\/a> http:\/\/www.oncologynurseadvisor.com\/side-effect-management\/letermovir-found-to-reduce-incidence-of-cmv-in-certain-patients\/article\/642929\/<\/p>\n","protected":false},"excerpt":{"rendered":"

Usually, as development progresses from preclinical to a more advanced clinical stage, reality begins to set in: problems become apparent that were not anticipated, efficacy may be less than expected or hoped for, and the safety margins may shrink to a single-digit factor. In other words, as more data accrue, Continue reading The Letermovir Top-Line Results are Out \u2013 Or Are They?<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":3283,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":true,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[227,3,18],"tags":[1939,1271,2043,403,1546,1543,2048,2041,448,2044,2045,37,2047,1979,1583,2042,2049,33,1549,588,2051,1935,2050,2040,1548],"class_list":["post-3281","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent_literature","category-the_news","category-the_viewpoint","tag-aicuris","tag-allphase-pharma-consulting","tag-anti-rejection-drugs","tag-antibiotic-blog","tag-brincidofovir","tag-chimerix","tag-cmv-terminase-inhibitor","tag-cmv-therapy","tag-cyclosporine","tag-cytochrome-p450","tag-drug-drug-interactions","tag-ganciclovir","tag-gcv","tag-gvhd","tag-harald-reinhart","tag-hsct","tag-keytruda","tag-letermovir","tag-maribavir","tag-merck","tag-mk-8224","tag-mk-8228","tag-pembrolizumab","tag-publication-delay","tag-viropharma"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/04\/Letermovir-blog-slider.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-QV","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":3131,"url":"https:\/\/allphasepharma.com\/dir\/2017\/02\/02\/3131\/monoclonal-pursuit-cmv-therapeutic\/","url_meta":{"origin":3281,"position":0},"title":"The Monoclonal Pursuit of the Next CMV Therapeutic","author":"Harald","date":"February 2, 2017","format":false,"excerpt":"There is no doubt that immunity to human cytomegalovirus (CMV) is both cell-and antibody-mediated. Studies in transplant patients showed that absence of T-cell protection with\u00a0chemotherapy is a set-up for recurrent and severe CMV disease. It was also shown that patients with pre-existing CMV antibodies are less likely to develop CMV\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/02\/CMV-blog-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/02\/CMV-blog-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/02\/CMV-blog-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":192,"url":"https:\/\/allphasepharma.com\/dir\/2014\/05\/11\/192\/cmv-hyperimmune-globulin-data-inconclusive-but-new-drug-shows-promise\/","url_meta":{"origin":3281,"position":1},"title":"CMV Hyperimmune Globulin Data Inconclusive but New Drug Shows Promise","author":"Harald","date":"May 11, 2014","format":false,"excerpt":"Treating CMV was never easy making prophylaxis the preferred approach for HSCT patients. Since the late 80ies,\u00a0trials using hyperimmune globulin have come up with mixed results. While treatment was usually safe,\u00a0efficacy was a lot much harder to prove. \u00a0More specific monoclonal ab preparations directed against immunodominant surface glycoproteins did not\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":2328,"url":"https:\/\/allphasepharma.com\/dir\/2016\/02\/26\/2328\/brincidofovir-another-drug-fails-in-phase-3\/","url_meta":{"origin":3281,"position":2},"title":"Brincidofovir \u2013 Another Drug Fails in Phase 3","author":"Harald","date":"February 26, 2016","format":false,"excerpt":"It is sad to see a pivotal trial fail, and you have to wonder why we recently had several such late-stage \u2018mishaps\u2019. Take Tetraphase\u2019s eravacycline which failed in a Phase 3 cUTI trial. We have analyzed this drug's failure in\u00a0earlier blogs; there is reason to believe that inadequate dosing was\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"Chimerix - slider copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/Chimerix-slider-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/Chimerix-slider-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/Chimerix-slider-copy.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":3195,"url":"https:\/\/allphasepharma.com\/dir\/2017\/02\/28\/3195\/cmv-connections-paul-bunnell-negative-mononucleosis-changelings\/","url_meta":{"origin":3281,"position":3},"title":"CMV Connections: Paul-Bunnell Negative Mononucleosis and \u2018Changelings\u2019","author":"Harald","date":"February 28, 2017","format":false,"excerpt":"Mononuclesosis is an EBV infection that can be diagnosed with the heterophil antibody test developed by Paul and Bunnell. The test is based on the agglutination of sheep erythrocytes with the blood of EBV infected patients. P-B heterophil serology is negative in \u2018mononucleosis\u2019 caused by CMV. In this day and\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/02\/CMV-connections-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/02\/CMV-connections-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/02\/CMV-connections-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":2446,"url":"https:\/\/allphasepharma.com\/dir\/2016\/04\/21\/2446\/quo-vadis-cdi-drugs\/","url_meta":{"origin":3281,"position":4},"title":"Quo Vadis, CDI Drugs?","author":"Harald","date":"April 21, 2016","format":false,"excerpt":"There are only 3 CDI drugs in wider clinical use: vancomycin, metronidazole, and fidaxomicin. They are from totally different classes and have almost nothing in common except for proven efficacy in C. difficile infection (CDI). Like vancomycin, the entire group of glycopeptide drugs seems to have good activity against C.\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"CDI - slider copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/04\/CDI-slider-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/04\/CDI-slider-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/04\/CDI-slider-copy.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1800,"url":"https:\/\/allphasepharma.com\/dir\/2015\/08\/01\/1800\/qidp-drugs-4th-edition\/","url_meta":{"origin":3281,"position":5},"title":"QIDP Drugs – 4th Edition","author":"Harald","date":"August 1, 2015","format":false,"excerpt":">>> For the latest QIDP list, please click HERE \u00a0<<< Since our\u00a0last QIDP blog from April 8, 2015, several new drugs have made the list which now includes 41 compounds. Below a table\u00a0which includes compound, sponsor\u00a0and development stage (Phase). It also indicates whether a drug has been\u00a0the topic of a\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"QIDP 4th edition","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/QIDP-4th-edition.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/QIDP-4th-edition.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/QIDP-4th-edition.jpg?resize=525%2C300 1.5x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/3281","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=3281"}],"version-history":[{"count":5,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/3281\/revisions"}],"predecessor-version":[{"id":3288,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/3281\/revisions\/3288"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/3283"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=3281"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=3281"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=3281"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}